Author Theory Darmani, 2002; Woods et al. 2014 In theory the antiemetic effect of cannabis is mediated by the binding of D9-THC to CB1as a partial agonist, producing antiemesis at low doses and hyperemesis at high doses. Woods et al., 2014 In genetically susceptible individuals, high doses of cannabis could be mediated by a disorder of hepatic cytochrome p450 which metabolizes D9-THC, producing an increase in its concentration. Allen et al., 2004 In genetically susceptible individuals, the high liposolubility of D9-THC would mediate an overaccumulation in fatty tissue. Allen et al., 2004 Bathing in hot water may relieve a false sensation of cold mediated by the effect of D9-THC at the level of CB1 located in the hypothalamus. Allen et al., 2004 Bathing in hot water may relieve a real sensation of cold caused by vasoconstriction of the superficial capillaries and vasodilatation of the deep capillaries produced by the union of D9-THC to CB1 C annabis is one of the most commonly used addictive substances worldwide (United Nations Office on Drugs and Crime, n.d.). In Spain, it is the illegal psychoactive substance used most widely at some point in life in the general population (27.4%), and the substance tried at the earliest age for the first time (18.7 years) (Spanish Observatory on Drugs, 2012; Delegación del Gobierno para el Plan Nacional sobre Drogas, 2010) .
The effects of cannabinoids on the organism are mediated by the binding of exogenous cannabinoids found in the marihuana plant to the endocannabinoid receptors (CB1 and CB2) widely distributed throughout the organism (Table 1) . Of the 66 exogenous cannabinoids, Delta-9-tetrahydrocannabinol (D9-THC) is the psychoactive component via its binding to the CB1 receptor.
The study of the effects of D9-THC on the organism has enabled the use of cannabis for therapeutic purposes (Duran & Capellà, 2004; Lorenzo & Leza, 2000) , and one example of this is its application as an antiemetic for controlling nausea and vomiting in chemotherapy patients (Adler & Colbert, 2013; Rodriguez de Fonseca & Navarro, 2000) .
In contrast to these antiemetic properties, in 2004 nine cases of a new syndrome, named cannabinoid hyperemesis (CHS), were published. This syndrome affects chronic cannabis users and is characterized by cyclical episodes of uncontrollable vomiting and compulsive bathing in hot water. These episodes subsided when abstaining from the substance and reappeared on renewed consumption (Allen, de Moore, Heddle, & Twartz, 2004) .
Since the publication of Allen et al. (2004) until June 2014, 74 new cases were reported in various European countries, four of them in Spain (Aguilar-Urbano, Perez-Asia, Navarro-Jarabo, & Sánchez-Cantos, 2011; Alfonso, Ojeda, & Moreno-Osset, 2006; Ochoa-Mangado, Jiménez, Salvador, & Madoz-Gúrpide, 2013; Roca-Pallín, López-Pelayo, Sugranyes, & Balcells-Oliveró, 2013) .
Some diagnostic criteria have been put forward for CHS (Table 2) (Simonetto, Oxentenko, Herman, & Szostek, 2012; Sontineni, 2009) , as well as an algorithm for the diagnosis and treatment of the syndrome (Wallace, 
Essential criterion
Chronic consumer of cannabis: longer than one year.
Main criteria
Severe nausea and vomiting Improvement with cannabis abstinence Relief of symptoms with bathing in hot water Epigastric or periumbilical abdominal pain
Supporting criterion
Younger than 50 years of age Loss of weight greater than 5 kilos Symptoms predominantly in the mornings
Normal bowel habits
Normal laboratory test, radiography and endoscopy results , Garmany, & Jelley, 2011) . However, the etiology of CHS is still unknown, and Table 3 summarizes the pathophysiological theories so far proposed for CHS. Given this context, treatment for acute episodes is symptomatic (Table 4 ). The pathophysiology of CHS, and in more detail the clinical practice and therapeutic guidelines for the treatment of acute episodes can be found in the publications of the cases.
Andrews
The first diagnosis of CHS was made in Mataró hospital in 2012. The patient was a 35-year old man, a chronic consumer of cannabis presenting with episodes of hyperemesis since 2002 and diagnosed with psychogenic vomiting. On the diagnosis of CHS, medical units of the hospital were alerted to the new medical condition, after which five new cases of CHS were identified up until June 2014 (Table 5) .
Similarly to the cases previously published (Table 6 ), in this series of six new cases an average of period of over a year passed between initial symptoms and correct diagnosis of CHS. During this time, patients were subjected to medical tests with negative results, and more the 50% of patients were hospitalized at least once for etiological analysis.
With the aim of providing information about this new clinical condition and facilitating prompt diagnosis of CHS, this study offers a summary of previously published cases and a description of new cases diagnosed in Mataró hospital.
Method

Reports of new cases
Six adult patients (minimum age 22) labeled with the letters A, B, C, D, E, F were treated in various units of Mataró hospital between November 2012 and June 2014 for uncontrollable vomiting and hot baths, and diagnosed with CHS (Table 4) . Three patients were referred by the emergency department to the emergency psychiatric unit to assess their "self-induced vomiting" and potomania (patients A, B and D). One patient was referred by a primary healthcare physician to a drug addiction center for cannabis cessation treatment (patient E); and two patients were hospitalized in the surgical unit for a study of vomiting, during which time consultation with a psychiatrist was sought on the grounds of anxiety (patients C and F).
Summary of published cases
A bibliographic review was carried out using the online PubMed database.
The search terms "cannabinoid hyperemesis syndrome" and "cannabinoid hyperemesis" were used. No time limits were set. All articles in English, Spanish, German, and French with explicit reference to this medical condition in the title and published prior to June 2014 were selected.
Of the 60 articles selected, 44 corresponded to reports (Table 6 ). One of these was excluded because it was a retrospective survey (Simonetto, Oxentenko, Herman, & Szostek, 2012) . Four articles corresponded to bibliographic reviews (Galli, Andari, & Friedenberg, 2011; Nicolson, Denysenko, Mulcare, Vito, & Chabon, 2012; Sun & Zimmermann, 2013; Wallace et al., 2011) , one of which also reports four cases (Nicolson et al., 2012) ; ten articles were letters to the editor (Aguilar- Urbano et al., 2011; Alfonso et al., 2006; Budhraja, 2009; Roca-Pallín et al., 2013; Roche & Foster, 2005; Roelofs, Vorel, Vorel-Havelkova, & Brombacher-Heerlen, 2005; Sannarangappa & Tan, 2009; Singh & Coyle, 2008; Torka & Sharma, 2012; Wolfhagen, 2014) of which seven also reported cases (Aguilar-Urbano et al., 2011; Alfonso et al., 2006; Roca-Pallín et al., 2013; Roche et al., 2005; Sannarangappa et al., 2009; Torka et al., 2012; Wolfhagen, 2014) . Finally, two articles consisted of clinical notes, without presenting a case (Francis, 2011; Sullivan, 2010) .
A table summarizing the published clinical cases of CHS up to June 2014 was drawn up (Table 5) . Table 5 presents a summary of the clinical features of the six patients diagnosed with CHS in Mataró hospital between November 2012 and June 2014. There were five men (83%) and one woman (17%), with an average age of 28.3 and average onset age of cannabis use of 16. All patients said they started smoking cannabis recreationally and continued using it for its anxiolytic effect.
Results
Series of six new cases identified in Mataró hospital
The average quantity and frequency of cannabis use was 7.5 cigarettes per day (with a minimum of less than 1 and a maximum of 12 cigarettes per day). One patient (B) described smoking less than one cigarette per day. All other patients said they smoked more than one cannabis cigarette a day. All patients affirmed that they had been smoking cannabis for at least a year before the first acute episode of CHS; the average was 5.5 years (minimum 2, maximum 11).
The average length of time between the onset of symptoms and diagnosis of CHS was 6.1 years (minimum 1, maximum 10). During this period, the patients went to the emergency department an average of ten times with incoercible vomiting and were subjected to etiological analysis which included at least one abdominal X-ray, an upper endoscopy and a blood test per patient. Three of the six patients (C, E and F) had to be admitted to the surgery department for these and other diagnostic tests. However, none of these analyses detected any somatic pathology which could cause vomiting and compulsive hot bathing.
During acute episodes, patients needed treatment in the emergency department, where it was observed that the six patients had a generally uncooperative attitude and suffered from anxiety and compulsive hot bathing, taking up to ten baths a day (patient A) and at least four (patient D). Three patients had polydipsia (A, C and E). All six patients achieved clinical remission after an average of 3.6 days of cannabis abstinence (minimum 2, maximum 5), coinciding with the length of their stay in the emergency ward for the treatment of acute CHS symptoms. It was an enforced abstinence given that they were in hospital.
For the symptomatic treatment of the acute CHS episode, the six patients received metoclopramide, 20-30 mg/ day intramuscularly, and ondansetron in 4 mg/day doses of intravenously. As an anxiolytic, diazepam was administered in doses of up to 40 mg/day orally. In acute episodes of vomiting, patient A was uncooperative, demanding treatment, distressed and suffering from psychomotor agitation; up to 40 mg/day of olanzapine was therefore administered orally or intramuscularly, and up to 20 mg/day of haloperidol administered intramuscularly or intravenously. The use of these drugs brought about a temporary therapeutic response, with relief of both nausea and anxiety for a minimum of one and a maximum of four hours, af- ter which symptoms manifested themselves again with the same degree of intensity observed before the respective drug was administered. After the CHS diagnosis, all patients were advised to abstain from cannabis use and were offered cessation treatment, which they accepted and to which responded differently.
Up until the presentation of this study, five patients (A, B, C, E and F) were monitored by drug dependency units. Of these, B, C and E achieved continued cannabis abstinence and a consequent absence of new CHS episodes. Of those who continued using cannabis, patient A relapsed into regular consumption and had on average one episode of acute CHS per month, while patient F reported reducing cannabis consumption from three to one cigarettes per day, without renewed CHS episodes being observed during outpatient monitoring.
The patient who abandoned treatment (D), did not register again for CHS treatment in emergency or primary care.
Summary of previously published cases
A total of 83 published cases of CHS were found (Table  5 ). The average age was 29.57 years (standard deviation 8.43), with a majority of male patients (72.2% of cases).
The average onset age of cannabis use was 17.38 (SD 6.69), and the average age when vomiting began was 25.89 (SD 8.239). The period of time between the onset of symptoms and diagnosis of CHS was observed to be between less than one year and 29 years (average 3.01 years, SD 4.1 years). Bathing in hot water was present in 91% of cases.
The described treatments administered were of a symptomatic nature. All studies concur in observing that standard antiemetics had "little or no" effect. The drugs used in treatment are summarized in Table 4 .
Regarding the advice that continued abstinence is the most effective treatment for CHS, differences depending on the type of publication were observed. Giving this advice to patients was mentioned in 70 of the 83 cases. Of these 70 patients, 59 (84.2%) reported abstinence, while 11 patients reported maintaining use. Of the 59 remaining abstinent, 8 suffered new CHS episodes. In 13 cases the corresponding article failed to mention whether the advice to remain abstinent once CHS was diagnosed was given to the patients concerned.
Discussion
The six patients diagnosed with CHS in Mataró hostpital met the diagnostic criteria proposed by Simonetto et al. (2012) presented in Table 2 . As observed in earlier publications, the patients were young, mostly male and had been suffering cyclic vomiting for more than a year. They had also been diagnosed wrongly and been subjected to etiological analyses with negative results.
After the first case of CHS was identified in Mataró hospital, the different medical units were informed about this new condition and patients presenting with cyclic vomiting and having a history of chronic cannabis consumption were subsequently referred to the mental health department for possible CHS. In such cases, hot bathing proved to be a decisive element for the correct diagnosis. This clinical sign, which was proposed as pathognomic of CHS (Wallace et al., 2011) was described by the six patients diagnosed in Mataró hospital, matching the observations made in the previously published cases (hot bathing is reported in 91%). This "compulsive" bathing is described as a learned behavior. During the hyperemetic phase, patients note their symptoms relieved during their usual bathing and therefore repeat the behavior. The relief observed is proportional to the water temperature (Allen et al., 2004) . In terms of frequency, the description in the published cases is varied. In one report, for example, a patient had 15 baths a day (Mohammed, Panchoo, Bartholemew, & Maharaj, 2013) , and in another, a patient claimed to spend four hours a day in the bath (Cox, Chhabra, Adler, Simmons, & Randlett, 2012) . In our series, patient A "needed" more than ten baths per day, and the rest between three and five per day. As a complication of the bathing, erytheme ab igne was identified in one of the patients described who took five or six hot baths daily (Kraemer, La Hoz, & Willig, 2013) .
During acute episodes of CHS, the six patients diagnosed in our hospital needed intravenous rehydration and were kept under observation in the emergency department for a minimum of 48 hours. In addition, patient A was admitted to intensive care on two occasions with symptoms of acute renal failure, a complication described in one previously published case (Habboushe & Sedor, 2014) .
Other complications of CHS described in previous publications are: weight loss (Allen et al., 2004; Singh et al., 2007) and esophagitis (Allen et al., 2004; Chang & Windish, 2009; Sontineni, 2009) .
It must be noted that abstinence was not observed in the all the cases where patients were offered medical advice about the link between cannabis consumption and CHS. In our series of cases, the patient with the greatest number of acute episodes of CHS and with the most serious complications (patient A), is the only one who has continued using cannabis habitually (and subsequently suffered monthly episodes of CHS) to date. This situation is consistent with the deleterious effect cannabis can have on the control of decision-making (Alameda-Bailén, Salguero-Alcañiz, Merchán-Clavellino, & Paíno-Quesada, 2014), which increases the likelihood among susceptible individuals of continuing consumption, and with it the episodes of CHS. 
Conclusions
The effects of exogenous cannabinoids on the organism are still not known in their entirety. In the context of the high prevalence of cannabis consumption in Spain, however, we consider it necessary to raise the awareness of healthcare providers about the existence of this syndrome, since a timely diagnosis can avoid unnecessary examinations, which are unpleasant for the patient and costly for the healthcare system.
Further studies are necessary in order to understand the pathophysiological mechanism by which cannabis induces hyperemesis.
Given that the treatment of acute CHW episodes is symptomatic, and that hot bathing constitute a learned behavior which relieves the symptoms of nausea and vomiting, we propose that this behavior is accepted as part of the treatment. For example, agreement could be reached with the patient, setting the number of baths per day and the most suitable temperature to prevent health risks to the patient during the acute phase of CHS.
Limitations of the study
In the summary of cases published to date, articles were included which were written in a variety of formats, with some of them omitting information included in Table 6 . When studying the data in this table, only those patients describing a feature in the respective publication were taken into account in its analysis.
